Natixis Arcellx, Inc. Transaction History
Natixis
- $22 Billion
- Q2 2025
A detailed history of Natixis transactions in Arcellx, Inc. stock. As of the latest transaction made, Natixis holds 80 shares of ACLX stock, worth $6,805. This represents 0.0% of its overall portfolio holdings.
Number of Shares
80Holding current value
$6,805% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ACLX
# of Institutions
219Shares Held
49.1MCall Options Held
245KPut Options Held
885K-
Paradigm Biocapital Advisors LP New York, NY4.65MShares$395 Million14.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.94MShares$336 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$319 Million20.45% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$299 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$258 Million4.37% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.73B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...